logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

 


Intercept Pharmaceuticals (ICPT) Sees Pullback from Record Gains

By  +Follow January 14, 2014 12:05PM
Share:
Tickers Mentioned:

Intercept Pharmaceuticals (ICPT) continued its wild, roller-coaster ride on Tuesday, with a second-straight day of major losses. Intercept made news last week after its treatment for fatty liver disease, obeticholic acid (OCA), had a Phase II clinical trial halted early because of its efficacy. Shares spiked, then jumped again on the second day after the stock received a raft of massive upgrades from major analysts.

However, this week appears to have seen Intercept return to earth. Shares dropped nearly 20 percent on Monday, and Tuesday saw losses in excess of 30 percent, making the two-day loss nearly 45 percent of its share value. That still has Intercept sporting a five-day gain approaching 450 percent, so investors are hardly sweating recent losses, but it does have the stock returning from the rarified air it reached by the close of markets on Friday.

ICPT Sheds Value on CEO Comments

The plummet for Intercept could be attributed to comments from CEO Mark Pruzanski that his company will most likely need to partner with a larger company to bring OCA to market; a deal that would most likely eat into any potential profits.

“[Intercept’s plan] is very much to build a commercial capability,” the he said in a phone interview with Bloomberg. “But large pharmaceutical companies are very good at this kind of thing. And the overarching responsibility here is to do what we can in a responsible way to get” OCA to patients if it’s approved.

“If that can be done in a more expedited fashion with a partner, that’s something we should consider,” he continued.

However, while these comments from Monday are clearly a factor, profit-taking by traders satisfied with last week’s massive gains and anticipating a market pull-back is probably a contributing factor as well as share-volume continued at very high levels.

Concerns Over Cholesterol Levels in OCA Patients Also a Factor

The revelation that the study showed rising cholesterol levels for the patients taking OCA as compared to those on a placebo could also be weighing on Intercept’s stock. The details of the study were included in a Sunday press release from Intercept.

"OCA is an FXR agonist and we have known for a long time that it is involved in many aspects of lipid metabolism," said Pruzanski in the release. "An important part of the rationale for advancing our drug in NASH is that by activating FXR in the liver, we believe that it reduces the excess lipid load which is a causal factor in the disease. In addition, there is preclinical evidence that by activating FXR systemically, OCA is able to shunt excess lipids away from collecting in arteries and other organs which could also be beneficial. It is in any case clear that the lipid changes seen in OCA-treated patients are part of a complex set of mechanisms and we are already conducting further studies to gain a more complete understanding of the clinical implications."

The timing of the release and the major decline in shares would seem to indicate that the cholesterol concerns may also be part of the picture this week.

“[While the cholesterol] link is not new news, we believe many investors are seeing it now for the first time,” wrote Oppenheimer & Co. analyst Akiva Felt in a note to clients.

While the Phase II trial showed promising results, some still noted that OCA is still far from approval even if it appears nearly certain to reach that end point.

“What we have is a proof of concept study,” said Nezam Afdhal, head of hepatology at Beth Israel Deaconess Medical Center in Boston. “‘How that becomes a registration trial and an approvable drug is a million-dollar question.’’

ICPT Continues to Move Price for Galectin, Others

The explosion of Intercept’s stock, as well as that of other pharma companies developing similar therapies, indicates that the potential for a successful treatment for fatty liver disease, which is estimated to affect 5 percent of the population, took the markets by surprise to some degree.

And, once again, the markets appeared to treat companies with potential treatments for fatty liver disease as a monolith to some degree, with Intercept's declines appearing to trigger similar declines among its competitors in the fatty liver disease sphere.

Shares in Galectin Therapeutics (GALT) plunged over 12 percent Tuesday to make its two-day losses over 20 percent, while Conatus Pharmaceuticals (CNAT) lost almost 2.75 percent Tuesday for two-day losses just under 20 percent.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for icpt
Yu Zhu
28 Jul 15 10:29:57
RT @dougheuringaria: JMP Orphan Disease Index $BLUE $QURE $FOLD $ICPT $ISIS http://t.co/lWrMG8fIJL
Steven Dickman
28 Jul 15 10:16:16
RT @dougheuringaria: JMP Orphan Disease Index $BLUE $QURE $FOLD $ICPT $ISIS http://t.co/lWrMG8fIJL
Tchoung Tchoung
28 Jul 15 08:47:44
RT @okim59: $Genfit....36.18€ -0.56% $ICPT.....$270, +1.63%
jjjj
28 Jul 15 08:27:24
RT @okim59: $Genfit....36.18€ -0.56% $ICPT.....$270, +1.63%
Okim59
28 Jul 15 08:24:53
$Genfit....36.18€ -0.56% $ICPT.....$270, +1.63%
J B
28 Jul 15 07:40:46
RT @sharkbiotech: $ESPR so reminds me of $ICPT 7-8 months ago was in the toilet then once it became clear FDA wouldnt need CVOT stock doubl…
Sasha Damouni
28 Jul 15 07:19:55
BMO pushing $ICPT's sales inflection past 2016 for primary biliary cirrhosis indication given need to educate prescribers and payer review
DailyStockPicks
28 Jul 15 07:19:27
$OCLS cheap health care stock. Price target of $5. 200%+ upside $FLR $CNC $ICPT $ZAYO $GK $INN investors read http://t.co/rWpJvFEbwZ
Russell Barbour
28 Jul 15 07:16:04
Millionaire trading student http://t.co/GSuqF6jxy8 made millions learning to trade from http://t.co/ui9ZEGEOU8 $AAPL $CNAT $ICPT
shmittahcapital
28 Jul 15 07:05:49
@sharkbiotech difference is very few bot $icpt then & basically every1 on $twtr bot $espr fri
Dan Rosenblum
28 Jul 15 07:00:13
$ESPR so reminds me of $ICPT 7-8 months ago was in the toilet then once it became clear FDA wouldnt need CVOT stock doubled
Me Likeitalot
28 Jul 15 06:55:27
RT @dougheuringaria: JMP Orphan Disease Index $BLUE $QURE $FOLD $ICPT $ISIS http://t.co/lWrMG8fIJL
Billy
28 Jul 15 06:37:48
Just seen that I got my fill on $ICPT Aug 370 calls @. 35 yesterday
Douglas Allan
28 Jul 15 06:27:26
$ICPT's OCA sales "inflection" may be pushed past 2016: BMO
Don H
28 Jul 15 06:20:16
RT @dougheuringaria: JMP Orphan Disease Index $BLUE $QURE $FOLD $ICPT $ISIS http://t.co/lWrMG8fIJL
Hot sOWce
28 Jul 15 05:27:58
RT @dougheuringaria: JMP Orphan Disease Index $BLUE $QURE $FOLD $ICPT $ISIS http://t.co/lWrMG8fIJL
True about ...
28 Jul 15 05:15:41
RT @GeryDIVRY: @genfit_pharma $ICPT $GNFTF regarding this article … increasing LDL is a very bad idea for NASH Patients..
shmittahcapital
28 Jul 15 05:10:06
$gild earnings don't be surprised if the 3 "targets" $vrtx $kite $icpt close up today....
Kykko
28 Jul 15 04:44:50
RT @GeryDIVRY: @genfit_pharma $ICPT $GNFTF regarding this article … increasing LDL is a very bad idea for NASH Patients..
dougheuring
28 Jul 15 04:24:07
BMO $ICPT http://t.co/bJKGD3cyCX
Gery DIVRY
28 Jul 15 03:44:19
@adamfeuerstein $ICPT $GNFTF did you noticed that ? http://t.co/xbjS4u0Tj9
julien
28 Jul 15 03:38:22
RT @GeryDIVRY: @adamfeuerstein during the last 6 month , the $ICPT insiders have sold 60% of their shares ?? http://t.co/86MgyTk3iM”
True about ...
28 Jul 15 03:29:58
RT @GeryDIVRY: during the last 6 month , the $ICPT insiders have sold 60% of their shares ?? do they know something we dont know ? http://t…
Franck Maloni
28 Jul 15 02:13:11
RT @GeryDIVRY: @genfit_pharma $ICPT $GNFTF regarding this article … increasing LDL is a very bad idea for NASH Patients..
Bagheera VAL
28 Jul 15 01:39:43
RT @GeryDIVRY: $GNFT $ICPT $GNFTF Preparing the respecting Phases III you should notice that : http://t.co/IJvbzXeJCR
Kristina Duering
28 Jul 15 01:27:13
RT @GeryDIVRY: during the last 6 month , the $ICPT insiders have sold 60% of their shares ?? do they know something we dont know ? http://t…
jjjj
28 Jul 15 01:24:54
RT @GeryDIVRY: during the last 6 month , the $ICPT insiders have sold 60% of their shares ?? do they know something we dont know ? http://t…
nicolas coutant
28 Jul 15 01:02:18
RT @GeryDIVRY: during the last 6 month , the $ICPT insiders have sold 60% of their shares ?? do they know something we dont know ? http://t…
Gery DIVRY
28 Jul 15 00:43:56
@adamfeuerstein during the last 6 month , the $ICPT insiders have sold 60% of their shares ?? http://t.co/86MgyTk3iM”
niko19
28 Jul 15 00:43:50
RT @GeryDIVRY: during the last 6 month , the $ICPT insiders have sold 60% of their shares ?? do they know something we dont know ? http://t…
Pels André
28 Jul 15 00:22:10
RT @GeryDIVRY: during the last 6 month , the $ICPT insiders have sold 60% of their shares ?? do they know something we dont know ? http://t…
Esenka
28 Jul 15 00:21:20
RT @GeryDIVRY: during the last 6 month , the $ICPT insiders have sold 60% of their shares ?? do they know something we dont know ? http://t…
PatAubagne
28 Jul 15 00:18:21
@GeryDIVRY no of course but the $ICPT insiders know #OCA and #GFT505...
TooTiX
28 Jul 15 00:09:03
RT @GeryDIVRY: during the last 6 month , the $ICPT insiders have sold 60% of their shares ?? do they know something we dont know ? http://t…
Vito
28 Jul 15 00:03:02
RT @dougheuringaria: JMP Orphan Disease Index $BLUE $QURE $FOLD $ICPT $ISIS http://t.co/lWrMG8fIJL
dafffyl
27 Jul 15 23:53:56
RT @GeryDIVRY: during the last 6 month , the $ICPT insiders have sold 60% of their shares ?? do they know something we dont know ? http://t…
Raj R
27 Jul 15 19:25:33
RT @dougheuringaria: JMP Orphan Disease Index $BLUE $QURE $FOLD $ICPT $ISIS http://t.co/lWrMG8fIJL
Biotech Supernova
27 Jul 15 18:06:38
RT @dougheuringaria: JMP Orphan Disease Index $BLUE $QURE $FOLD $ICPT $ISIS http://t.co/lWrMG8fIJL
NT
27 Jul 15 17:42:54
RT @dougheuringaria: JMP Orphan Disease Index $BLUE $QURE $FOLD $ICPT $ISIS http://t.co/lWrMG8fIJL
dougheuring
27 Jul 15 17:40:36
JMP Orphan Disease Index $BLUE $QURE $FOLD $ICPT $ISIS http://t.co/lWrMG8fIJL
emmanuel
27 Jul 15 15:57:27
RT @GeryDIVRY: during the last 6 month , the $ICPT insiders have sold 60% of their shares ?? do they know something we dont know ? http://t…
Gery DIVRY
27 Jul 15 15:42:55
during the last 6 month , the $ICPT insiders have sold 60% of their shares ?? do they know something we dont know ? http://t.co/86MgyTk3iM
PennyStock Zone
27 Jul 15 12:00:38
http://t.co/T1OENoRe1I <- Fous4x2 review invest in your #trading education! $ABEV $ICPT $AA $AMBA #stocks $FB $TWTR
binaryoptionsocial
27 Jul 15 08:45:54
Visit http://t.co/ecokY7Xk32 for info on $GPRO, $AMZN, $ICPT and $ARIA - #NASDAQ http://t.co/oVh1sIdkcD http://t.co/Csk7miIhta
NASDAQStocks
27 Jul 15 08:45:06
Visit http://t.co/dObsQpoZJP for info on $GPRO, $AMZN, $ICPT and $ARIA - #NASDAQ http://t.co/rTfUF0B2Yl
Zach Rohelier
27 Jul 15 08:18:31
I still think $GILD buys $ICPT
Okim59
27 Jul 15 06:53:43
RT @SleekMoneycom: RBC Capital Reaffirms Outperform Rating for Intercept Pharmaceuticals $ICPT http://t.co/pXNNc3KkW6
idgaftw
27 Jul 15 06:38:30
The bloodbath that is my whole portfolio: $BLUE $CLLS $ESPR $FPRX $HALO $ICPT $JUNO $LBIO $MEIP $RCPT $RLYP $TGTX $THLD $TRIL $TWTR
Sleek Money
27 Jul 15 06:35:38
RBC Capital Reaffirms Outperform Rating for Intercept Pharmaceuticals $ICPT http://t.co/pXNNc3KkW6
TooTiX
27 Jul 15 06:19:08
RT @GeryDIVRY: @genfit_pharma $ICPT $GNFTF regarding this article … increasing LDL is a very bad idea for NASH Patients..
				
				
By  +Follow January 14, 2014 12:05PM
Share:

Comments

 

blog comments powered by Disqus

 Today's Must Reads

5 Small-Cap Energy with Hedges to Survive Oil's Bear Market


DraftKings and FanDuel: The New Face of Legalized Online Sports Betting

Is the Market Paying the Toll of Tech?

What Will Uber Look Like in the Future?


How Dodd-Frank Divides Political Parties Prior to 2016 Election

 

Apple (AAPL) is expected to announce its latest quarterly earnings next week. As the most valuable company by mark... in Equities.com's Hangs on LockerDome

About us

Equities.com is an advanced financial data portal and social network designed to connect self-directed investors with the world’s most innovative startup and small cap companies. Through our in-depth coverage of small cap markets, comprehensive research and stock valuation reports, state of the art issuer products, and world class events, Equities.com provides the social tools and insight that drive tomorrow’s investment relationships and opportunities.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.

Login or Register

LOG IN